Neurodegenerative diseases
Conditions
Interventions
None listed
Sponsors
Gifu Pharmaceutical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: <Amyotrophic lateral sclerosis (ALS)> Clinical feature or electrophysiological abnormality from upper and lower motor neuron disorder. Clinical feature of upper motor neuron disorder is determined as pathological reflex and clonus. Clinical feature of lower motor neuron disorder is determined as muscular weakness, amyotrophy, and muscular fasciculation. <Idiopathic basal ganglia calcification (IBGC)> Conspicuous calcification is observed in the basal ganglia and/or dentate nucleus on CT scanning image. Calcification is bilateral and symmetrical. Idiopathic (absence of biochemical abnormalities, and an infections, toxic, or traumatic cause).
Exclusion criteria
Exclusion criteria: <Amyotrophic lateral sclerosis (ALS)> Exclude the following diseases. Other motor neuron disorders, motor neurophathy, cervical spondylosis, and inflammatory myopathy such as inclusion body myositis. <Idiopathic basal ganglia calcification (IBGC)> To exclude diseases which show calcification, because of some causes such as hypoparathyroism, pseudo hypoparathyroism, pseudopseudo hypoparathyroism (Albright's osteodystrophy), Down syndrome, collagen diseases, angiitis, infections, intoxication, trauma, radiation therapy and so on.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To lay the foundation for future researches of drug development for neurodegenerative diseases. | — |
Countries
Japan
Contacts
Public ContactIsao Hozumi
Gifu Pharmaceutical University Laboratory of Medical Therapeutics and Molecular Therapeutics
Outcome results
None listed